Is Inovio Back in the Coronavirus Vaccine Race?

Is Inovio Back in the Coronavirus Vaccine Race?

Source: 
Motley Fool
snippet: 

Inovio Pharmaceuticals (NASDAQ: INO) investors can breathe a little easier this week after the U.S. Food and Drug Administration lifted a partial clinical hold on the planned phase 2 study of the company's investigational coronavirus vaccine. The biotech can now move forward with that part of the trial. Adding to the good news, Inovio said the U.S. Department of Defense will fund the phase 2 and phase 3 trials. Inovio shares, down 34% since the announcement of the partial hold in late September, jumped nearly 15% in one trading session.